Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free ATRA Stock Alerts

Atara Biotherapeutics (ATRA) Financials

Atara Biotherapeutics logo
$7.90 -0.27 (-3.30%)
As of 07/24/2026 04:00 PM Eastern
Compare
Annual Income Statements for Atara Biotherapeutics

Annual Income Statements for Atara Biotherapeutics

This table shows Atara Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Consolidated Net Income / (Loss)		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Net Income / (Loss) Continuing Operations		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Total Pre-Tax Income 		-57 -79 -120 -231 -291 -307 -340 -228 -276 -85 33
Total Operating Income		 -58 -81 -122 -237 -296 -309 -340 -281 -276 -83 36
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 20 64 8.57 129 121
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 20 64 8.57 129 121
Operating Revenue		 - - - - 0.00 - 20 64 8.57 129 121
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 58 81 122 237 296 309 361 344 285 212 85
Selling, General & Admin Expense		 17 25 40 70 80 64 79 72 51 40 26
Research & Development Expense		 42 57 81 167 216 245 282 273 225 151 37
Other Operating Expenses / (Income)		 - - - - - 0.00 - - 8.89 21 21
Total Other Income / (Expense), net		 1.22 2.20 2.03 6.37 4.72 2.45 0.37 52 -0.11 -1.98 -3.14
Interest Expense		 - - - - - - - 0.37 5.29 4.62 3.79
Interest & Investment Income		 - - - - - - - 3.06 5.43 2.11 0.68
Other Income / (Expense), net		 1.22 2.20 2.03 6.37 4.72 2.45 0.37 50 -0.25 0.53 -0.03
Income Tax Expense		 -0.01 0.01 -0.01 -0.04 0.01 0.02 0.05 0.01 0.02 -0.01 0.03
Basic Earnings per Share		 ($2.24) ($2.75) ($4.00) ($5.27) ($5.67) ($4.15) ($3.63) ($2.24) ($65.19) ($11.41) $2.61
Weighted Average Basic Shares Outstanding		 25.58M 28.73M 29.86M 43.81M 51.31M 73.97M 93.67M 101.99M 4.24M 7.49M 12.54M
Diluted Earnings per Share		 ($2.24) ($2.75) ($4.00) ($5.27) ($5.67) ($4.15) ($3.63) ($2.24) ($65.19) ($11.41) $2.57
Weighted Average Diluted Shares Outstanding		 25.58M 28.73M 29.86M 43.81M 51.31M 73.97M 93.67M 101.99M 4.24M 7.49M 12.72M
Weighted Average Basic & Diluted Shares Outstanding		 25.58M 28.73M 29.86M 43.81M 51.31M 73.97M 93.67M 95.93M 119.36M 5.86M 8.18M

Quarterly Income Statements for Atara Biotherapeutics

This table shows Atara Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -70 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15
Consolidated Net Income / (Loss)		 -70 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15
Net Income / (Loss) Continuing Operations		 -70 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15
Total Pre-Tax Income 		-70 -60 -32 -19 -22 -13 38 2.39 -4.28 -3.41 -4.15
Total Operating Income		 -70 -60 -31 -18 -22 -12 39 3.20 -3.57 -2.56 -3.37
Total Gross Profit		 2.14 4.25 27 29 40 33 98 18 3.45 1.60 0.52
Total Revenue		 2.14 4.25 27 29 40 33 98 18 3.45 1.60 0.52
Operating Revenue		 2.14 4.25 27 29 40 33 98 18 3.45 1.60 0.52
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 72 64 59 47 62 45 59 14 7.03 4.16 3.89
Selling, General & Admin Expense		 12 11 11 8.91 10 9.44 11 6.51 3.99 4.28 3.60
Research & Development Expense		 57 50 46 33 44 29 27 7.31 2.93 -0.22 0.16
Other Operating Expenses / (Income)		 2.62 - 1.99 4.63 7.60 6.80 20 0.55 0.12 0.10 0.12
Total Other Income / (Expense), net		 -0.20 -0.48 -0.48 -0.82 -0.17 -0.51 -0.79 -0.81 -0.70 -0.84 -0.78
Interest Expense		 1.40 1.18 1.15 1.26 1.18 1.02 1.02 0.97 0.91 0.89 0.83
Interest & Investment Income		 1.22 0.71 0.60 0.45 0.46 0.60 0.24 0.14 0.20 0.10 0.05
Other Income / (Expense), net		 -0.03 -0.01 0.07 -0.01 0.56 -0.09 -0.01 0.02 0.00 -0.05 0.00
Income Tax Expense		 -0.02 0.01 0.02 0.00 -0.02 -0.02 0.00 0.00 0.03 - 0.00
Basic Earnings per Share		 ($16.40) ($14.27) ($5.65) ($3.10) ($2.93) ($1.70) $3.53 $0.20 ($0.32) ($0.27) ($0.29)
Weighted Average Basic Shares Outstanding		 4.26M 4.24M 5.62M 6.14M 7.47M 7.49M 10.76M 12.20M 13.56M 12.54M 14.08M
Diluted Earnings per Share		 ($16.40) ($14.27) ($5.65) ($3.10) ($2.93) ($1.70) $3.50 $0.19 ($0.32) ($0.27) ($0.29)
Weighted Average Diluted Shares Outstanding		 4.26M 4.24M 5.62M 6.14M 7.47M 7.49M 10.85M 12.31M 13.56M 12.72M 14.08M
Weighted Average Basic & Diluted Shares Outstanding		 101.92M 119.36M 120.42M 4.92M 5.76M 5.86M 5.96M 7.02M 7.21M 8.18M 9.01M

Annual Cash Flow Statements for Atara Biotherapeutics

This table details how cash moves in and out of Atara Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.85 24 33 -19 14 126 -94 -14 -67 -0.81 -17
Net Cash From Operating Activities		 -37 -60 -88 -180 -236 -181 -221 -270 -193 -69 -51
Net Cash From Continuing Operating Activities		 -37 -60 -86 -180 -236 -181 -221 -270 -193 -69 -51
Net Income / (Loss) Continuing Operations		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Consolidated Net Income / (Loss)		 -57 -79 -119 -231 -291 -307 -340 -228 -276 -85 33
Depreciation Expense		 0.05 0.38 0.96 3.73 7.07 8.33 9.35 5.65 4.83 5.05 2.12
Amortization Expense		 3.47 2.58 0.73 -1.89 -1.33 0.83 1.77 1.02 0.79 -0.24 0.26
Non-Cash Adjustments To Reconcile Net Income		 15 14 26 49 42 60 52 16 46 22 12
Changes in Operating Assets and Liabilities, net		 1.90 1.98 5.60 -0.20 7.21 57 57 -65 32 -11 -98
Net Cash From Investing Activities		 -220 84 100 -196 60 -121 22 203 124 8.62 18
Net Cash From Continuing Investing Activities		 -220 84 100 -196 60 -121 22 203 124 8.62 18
Purchase of Property, Plant & Equipment		 -0.29 -3.02 -20 -36 -5.73 -4.51 -11 -4.19 -1.22 -0.25 0.00
Purchase of Investments		 -380 -305 -176 -466 -270 -426 -301 -181 -84 -20 -7.89
Sale of Property, Plant & Equipment		 - - 0.00 0.00 0.16 - - 0.00 0.03 0.00 0.95
Sale and/or Maturity of Investments		 160 392 297 306 336 310 334 293 209 29 25
Net Cash From Financing Activities		 259 0.51 20 358 189 428 104 53 2.01 59 16
Net Cash From Continuing Financing Activities		 259 0.51 20 358 189 428 104 53 2.01 59 16
Repayment of Debt		 - 0.00 0.00 0.00 -0.49 -0.17 -0.02 -0.19 -0.96 -0.01 -0.00
Issuance of Common Equity		 0.44 0.60 20 72 196 430 105 24 3.06 60 16
Other Financing Activities, net		 259 -0.09 -0.36 285 -6.70 -1.91 -1.50 29 -0.09 -0.89 -0.25
Cash Interest Paid		 - 0.00 0.00 0.24 0.05 0.06 0.03 0.34 0.45 0.69 0.29
Cash Income Taxes Paid		 0.00 0.01 0.00 0.00 0.00 0.01 0.02 0.02 0.00 0.02 0.19

Quarterly Cash Flow Statements for Atara Biotherapeutics

This table details how cash moves in and out of Atara Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 19 -39 9.25 -3.77 15 -21 -11 2.92 -11 2.74 -0.12
Net Cash From Operating Activities		 -51 -50 -30 -11 -3.99 -24 -28 -7.32 -9.79 -5.70 -3.07
Net Cash From Continuing Operating Activities		 -51 -50 -30 -11 -3.99 -24 -28 -7.32 -9.79 -5.70 -3.07
Net Income / (Loss) Continuing Operations		 -70 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15
Consolidated Net Income / (Loss)		 -70 -60 -32 -19 -22 -13 38 2.39 -4.30 -3.41 -4.15
Depreciation Expense		 1.21 1.21 1.39 1.33 1.23 1.10 1.80 0.24 0.04 0.05 0.03
Amortization Expense		 -0.21 2.11 0.04 -0.01 -0.06 -0.21 0.26 -0.00 -0.08 0.08 0.00
Non-Cash Adjustments To Reconcile Net Income		 16 8.68 9.34 -6.74 8.01 11 4.47 7.28 -5.11 4.91 1.47
Changes in Operating Assets and Liabilities, net		 1.67 -1.96 -8.62 14 8.73 -23 -73 -17 -0.33 -7.33 -0.43
Net Cash From Investing Activities		 70 9.94 15 7.20 -17 3.38 17 -5.07 -2.42 8.44 0.00
Net Cash From Continuing Investing Activities		 70 9.94 15 7.20 -17 3.38 17 -5.07 -2.42 8.44 0.00
Sale and/or Maturity of Investments		 71 9.99 15 7.23 3.00 3.47 17 - 0.00 7.89 0.00
Net Cash From Financing Activities		 -0.21 1.51 24 -0.32 36 -0.33 -0.25 15 1.05 -0.00 2.95
Net Cash From Continuing Financing Activities		 -0.21 1.51 24 -0.32 36 -0.33 -0.25 15 1.05 -0.00 2.95
Repayment of Debt		 - -0.95 -0.23 0.22 - - - 0.25 - - 0.00
Issuance of Common Equity		 - 1.73 24 -0.09 36 -0.09 0.00 15 1.05 -0.00 2.95
Cash Interest Paid		 0.11 0.12 0.11 0.25 0.14 0.19 0.07 0.05 0.05 0.12 0.11

Annual Balance Sheets for Atara Biotherapeutics

This table presents Atara Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 325 264 218 392 343 588 468 376 166 109 20
Total Current Assets		 325 261 172 321 273 523 385 295 102 65 12
Cash & Equivalents		 24 48 79 61 74 200 106 93 26 25 8.48
Accounts Receivable		 - - - - 0.00 1.25 0.99 40 34 1.48 1.25
Other Current Assets		 - - - - - - 12 10 6.18 10 2.48
Plant, Property, & Equipment, net		 0.27 3.26 44 69 54 51 54 6.30 3.86 1.29 0.07
Total Noncurrent Assets		 0.11 0.10 1.46 1.77 16 14 30 75 60 43 7.95
Other Noncurrent Operating Assets		 0.11 0.10 1.46 1.77 16 14 30 75 60 43 7.95
Total Liabilities & Shareholders' Equity		 325 264 218 392 343 588 468 376 166 109 20
Total Liabilities		 9.88 10 40 53 52 126 189 250 265 206 59
Total Current Liabilities		 9.71 9.68 28 40 37 83 106 79 142 135 15
Accounts Payable		 1.45 2.78 15 3.72 7.96 7.12 17 6.87 3.68 4.37 0.13
Accrued Expenses		 5.64 2.41 4.01 19 8.34 16 13 25 17 7.98 0.08
Current Deferred Revenue		 - - - - 0.00 33 41 8.00 78 95 0.72
Current Employee Benefit Liabilities		 2.62 3.75 5.66 11 15 20 25 18 12 6.59 1.27
Other Current Liabilities		 - 0.74 3.27 6.41 5.73 6.06 9.06 21 32 21 13
Total Noncurrent Liabilities		 0.17 0.50 12 13 15 43 83 171 123 72 44
Other Noncurrent Operating Liabilities		 0.17 0.50 12 13 15 15 27 94 85 72 44
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 315 254 178 339 291 462 280 127 -99 -97 -39
Total Preferred & Common Equity		 315 254 178 339 291 462 280 127 -99 -97 -39
Total Common Equity		 315 254 178 339 291 462 280 127 -99 -97 -39
Common Stock		 414 431 475 867 1,109 1,587 1,745 1,822 1,870 1,957 1,983
Retained Earnings		 -98 -177 -297 -527 -818 -1,125 -1,465 -1,693 -1,969 -2,055 -2,022
Accumulated Other Comprehensive Income / (Loss)		 -0.52 -0.18 -0.15 -0.34 0.22 0.30 -0.37 -2.07 -0.20 0.01 0.00

Quarterly Balance Sheets for Atara Biotherapeutics

This table presents Atara Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 189 165 117 143 62 37 30 20
Total Current Assets		 119 106 62 92 27 25 18 12
Cash & Equivalents		 65 35 31 46 14 17 5.74 8.36
Accounts Receivable		 0.16 36 2.42 1.34 8.88 0.00 1.91 0.00
Other Current Assets		 9.39 8.13 5.80 9.21 4.32 2.45 2.81 3.81
Plant, Property, & Equipment, net		 4.63 2.99 2.32 1.66 0.29 0.18 0.15 0.06
Total Noncurrent Assets		 65 56 53 49 35 12 12 7.77
Other Noncurrent Operating Assets		 65 56 53 49 35 12 12 7.77
Total Liabilities & Shareholders' Equity		 189 165 117 143 62 37 30 20
Total Liabilities		 240 264 228 233 117 72 67 57
Total Current Liabilities		 79 181 148 156 48 15 18 5.65
Accounts Payable		 6.51 2.85 5.25 2.15 1.38 1.76 0.32 0.64
Accrued Expenses		 24 16 2.01 6.08 1.78 0.97 0.34 0.04
Current Deferred Revenue		 12 123 108 116 16 1.61 1.01 0.68
Current Employee Benefit Liabilities		 14 5.71 7.27 7.77 4.60 2.55 2.07 0.63
Other Current Liabilities		 23 33 26 24 24 7.67 14 3.65
Total Noncurrent Liabilities		 161 83 80 77 69 57 49 52
Other Noncurrent Operating Liabilities		 87 82 79 77 69 57 49 52
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -51 -98 -111 -91 -55 -35 -37 -37
Total Preferred & Common Equity		 -51 -98 -111 -91 -55 -35 -37 -37
Total Common Equity		 -51 -98 -111 -91 -55 -35 -37 -37
Common Stock		 1,858 1,903 1,909 1,951 1,961 1,979 1,982 1,989
Retained Earnings		 -1,909 -2,001 -2,020 -2,042 -2,017 -2,014 -2,018 -2,026
Accumulated Other Comprehensive Income / (Loss)		 -0.57 -0.06 -0.01 0.02 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Atara Biotherapeutics

This table displays calculated financial ratios and metrics derived from Atara Biotherapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 28,631,144.00 28,860,635.00 30,595,866.00 45,648,266.00 54,150,553.00 77,714,302.00 88,417,386.00 94,878,670.00 101,922,250.00 - 7,210,235.00
DEI Adjusted Shares Outstanding		 1,145,246.00 1,154,425.00 1,223,835.00 1,825,931.00 2,166,022.00 3,108,572.00 3,536,695.00 3,795,147.00 4,076,890.00 - 7,210,235.00
DEI Earnings Per Adjusted Shares Outstanding		 -49.96 -68.47 -97.64 -126.35 -134.34 -98.64 -96.17 -60.16 -67.73 - 4.53
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 212.55% -86.51% 1,404.02% -6.33%
EBITDA Growth		 -95.34% -41.62% -54.87% -94.28% -24.61% -4.28% -10.60% 31.82% -20.66% 71.14% 148.92%
EBIT Growth		 -104.17% -38.11% -51.20% -93.08% -26.10% -5.38% -10.92% 32.08% -19.60% 69.99% 143.21%
NOPAT Growth		 -107.59% -39.00% -49.59% -95.10% -24.70% -4.52% -10.16% 17.61% 1.61% 69.77% 161.34%
Net Income Growth		 -104.32% -38.15% -51.16% -93.07% -26.13% -5.38% -10.93% 32.88% -20.95% 69.07% 138.28%
EPS Growth		 60.14% -22.77% -45.45% -31.75% -7.59% 26.81% 12.53% 38.29% -20.95% 82.50% 122.52%
Operating Cash Flow Growth		 -112.71% -61.55% -45.78% -105.45% -31.07% 23.29% -22.00% -22.63% 28.64% 64.39% 25.87%
Free Cash Flow Firm Growth		 -78.54% -66.26% -63.81% -85.69% -14.17% 30.12% -26.54% 7.29% 7.72% 56.08% 17.92%
Invested Capital Growth		 -497.00% 61.62% 640.84% 150.84% 8.43% -222.35% -137.96% -26.93% -29.90% 7.40% 66.42%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 59.01% -10.33% 88.75% 28.38% -20.51%
EBITDA Q/Q Growth		 -18.69% 1.53% -16.44% -23.93% 0.83% 0.41% -3.41% 6.66% 6.12% 36.69% 30.47%
EBIT Q/Q Growth		 -21.06% 3.67% -16.69% -24.05% 0.54% 0.15% -3.45% 7.12% 5.36% 36.51% 37.02%
NOPAT Q/Q Growth		 -23.64% 3.58% -16.32% -24.08% 0.71% -0.65% -3.56% 5.99% 5.34% 36.40% 36.70%
Net Income Q/Q Growth		 -23.06% 3.67% -16.68% -24.03% 0.52% -0.93% -3.67% 7.60% 4.87% 35.86% 39.69%
EPS Q/Q Growth		 -136.96% 4.84% -15.27% -13.33% 7.50% 9.39% -3.42% 7.05% 4.87% 36.04% 48.55%
Operating Cash Flow Q/Q Growth		 -20.84% -19.45% -4.51% -22.05% -0.54% 23.19% -15.84% -9.12% 3.25% 27.40% 26.93%
Free Cash Flow Firm Q/Q Growth		 0.00% -17.42% -15.38% -10.14% -1.33% 29.02% -18.50% 2.74% -21.54% 20.34% 29.77%
Invested Capital Q/Q Growth		 -978.53% 73.71% 166.62% -21.78% -10.89% -245.03% -93.77% -46.07% 1.49% 11.37% 6.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,617.41% -352.82% -3,156.78% -60.57% 31.63%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,673.85% -441.25% -3,219.48% -64.71% 29.69%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,672.05% -363.32% -3,222.35% -64.30% 29.67%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,672.28% -359.12% -3,220.88% -66.23% 27.07%
Tax Burden Percent		 99.98% 100.01% 99.99% 99.98% 100.00% 100.00% 100.01% 100.01% 100.01% 99.99% 99.91%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 98.84% 99.95% 103.02% 91.32%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.09%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -27.36% -27.79% -55.37% -89.29% -92.43% -81.43% -91.69% -112.39% -2,014.86% 86.92% -48.15%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -853.52% -903.49% -692.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -64.40% -54.70% -101.95% -60.39% 55.40%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -64.41% -54.07% -101.91% -62.20% 50.55%
Return on Common Equity (ROCE)		 -27.36% -27.79% -55.37% -89.29% -92.43% -81.43% -91.69% -112.39% -2,014.86% 86.92% -48.15%
Return on Equity Simple (ROE_SIMPLE)		 -18.16% -31.15% -67.18% -68.08% -100.07% -66.32% -121.65% -180.28% 278.27% 87.79% 0.00%
Net Operating Profit after Tax (NOPAT)		 -41 -57 -85 -166 -207 -216 -238 -196 -193 -58 36
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.70% -308.87% -2,253.64% -45.30% 29.67%
Net Nonoperating Expense Percent (NNEP)		 -7.68% -7.69% -16.31% -27.19% -29.52% -23.75% -23.35% -10.40% -56.25% -57.13% -12.28%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 194.70% 60.04% -93.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 387.42% 112.55% 593.82% 30.93% 21.74%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,386.44% 428.69% 2,622.01% 117.48% 31.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,773.85% 541.25% 3,319.48% 164.71% 70.31%
Earnings before Interest and Taxes (EBIT)		 -57 -79 -120 -231 -291 -307 -340 -231 -276 -83 36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -76 -118 -229 -285 -297 -329 -224 -271 -78 38
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.40 1.62 3.11 4.68 3.07 3.30 4.98 2.46 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 2.40 1.62 3.11 4.68 3.07 3.30 4.98 2.46 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 68.51 4.90 6.10 0.59 1.08
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.99
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 25.06%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 33.48 43.95 20.10 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 50.26 1.07 0.05 0.26 1.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.19
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.40
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.40
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.01 -0.98 -0.92 -0.90 -1.01 -1.18 -1.51 -10.76 0.48 0.38
Leverage Ratio		 1.03 1.04 1.12 1.18 1.17 1.24 1.42 2.08 19.77 -1.40 -0.95
Compound Leverage Factor		 1.03 1.04 1.12 1.18 1.17 1.24 1.42 2.05 19.76 -1.44 -0.87
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 46.10 23.37 5.40 14.99 4.95 3.78 -1.58 -6.72 -22.29 -28.23 -126.90
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 33.43 26.93 6.23 8.04 7.43 6.31 3.64 3.74 0.72 0.48 0.82
Quick Ratio		 33.01 26.43 6.01 7.74 7.05 6.05 3.52 3.59 0.60 0.33 0.65
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -36 -60 -99 -183 -209 -146 -185 -172 -158 -70 -57
Operating Cash Flow to CapEx		 -12,812.41% -1,987.58% -432.49% -500.41% -4,228.75% -4,005.30% -2,084.33% -6,449.56% -16,108.26% -27,933.74% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -460.27 -29.98 -15.08 -15.06
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -725.01 -36.51 -14.89 -13.43
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -736.25 -36.74 -14.94 -13.18
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.15 0.03 0.94 1.87
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 18.19 3.09 0.23 7.25 88.32
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.39 2.12 1.69 50.07 176.70
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 20.06 118.29 1,582.30 50.37 4.13
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 20.06 118.29 1,582.30 50.37 4.13
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.58 -2.14 12 29 31 -39 -92 -116 -151 -140 -47
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -0.31 -0.61 -0.06 -0.89 -1.29
Increase / (Decrease) in Invested Capital		 -4.64 3.44 14 17 2.45 -70 -53 -25 -35 11 93
Enterprise Value (EV)		 435 154 387 1,276 633 1,025 1,022 68 0.39 34 122
Market Capitalization		 756 410 554 1,586 892 1,526 1,393 311 52 77 130
Book Value per Share		 $11.01 $8.79 $5.81 $7.42 $5.37 $5.95 $3.16 $1.33 ($0.97) ($16.89) ($5.34)
Tangible Book Value per Share		 $11.01 $8.79 $5.81 $7.42 $5.37 $5.95 $3.16 $1.33 ($0.97) ($16.89) ($5.34)
Total Capital		 315 254 178 339 291 462 280 127 -99 -97 -39
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -321 -256 -166 -310 -259 -501 -371 -243 -52 -43 -8.48
Capital Expenditures (CapEx)		 0.29 3.02 20 36 5.57 4.51 11 4.19 1.20 0.25 -0.95
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.79 -5.00 -22 -28 -23 -60 -92 -27 -92 -112 -11
Debt-free Net Working Capital (DFNWC)		 315 251 145 282 236 440 279 216 -40 -70 -2.71
Net Working Capital (NWC)		 315 251 145 282 236 440 279 216 -40 -70 -2.71
Net Nonoperating Expense (NNE)		 16 22 34 65 84 90 102 32 83 27 3.14
Net Nonoperating Obligations (NNO)		 -321 -256 -166 -310 -259 -501 -371 -243 -52 -43 -8.48
Total Depreciation and Amortization (D&A)		 3.51 2.97 1.69 1.85 5.74 9.16 11 6.68 5.62 4.81 2.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -454.41% -42.16% -1,075.80% -87.11% -9.27%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,370.87% 340.02% -470.75% -54.04% -2.24%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,370.87% 340.02% -470.75% -54.04% -2.24%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($56.00) ($68.75) ($100.00) ($131.75) ($141.75) ($103.75) ($90.75) ($56.00) ($65.25) ($11.41) $2.61
Adjusted Weighted Average Basic Shares Outstanding		 1.15M 1.16M 1.55M 1.85M 2.34M 3.34M 3.72M 4.08M 4.24M 7.49M 12.54M
Adjusted Diluted Earnings per Share		 ($56.00) ($68.75) ($100.00) ($131.75) ($141.75) ($103.75) ($90.75) ($56.00) ($65.25) ($11.41) $2.57
Adjusted Weighted Average Diluted Shares Outstanding		 1.15M 1.16M 1.55M 1.85M 2.34M 3.34M 3.72M 4.08M 4.24M 7.49M 12.72M
Adjusted Basic & Diluted Earnings per Share		 ($56.00) ($68.75) ($100.00) ($131.75) ($141.75) ($103.75) ($90.75) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.02M 1.15M 1.19M 1.75M 2.05M 2.96M 3.75M 3.84M 4.77M 5.86M 8.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -57 -85 -166 -207 -216 -238 -196 -193 -58 36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.70% -308.87% -2,253.64% -45.30% 29.67%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,672.05% -359.10% -3,220.70% -66.24% 27.09%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -619.24 -52.27 -17.97 9.45
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -526.43 -36.56 -12.66 9.45
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -630.48 -52.50 -18.02 9.70
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -537.67 -36.78 -12.71 9.70
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Atara Biotherapeutics

This table displays calculated financial ratios and metrics derived from Atara Biotherapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 101,102,152.00 101,922,250.00 119,359,230.00 120,416,138.00 4,915,049.00 - 5,858,909.00 5,961,391.00 7,023,032.00 7,210,235.00 8,178,114.00
DEI Adjusted Shares Outstanding		 4,044,086.00 4,076,890.00 4,774,369.00 4,816,646.00 4,915,049.00 - 5,858,909.00 5,961,391.00 7,023,032.00 7,210,235.00 8,178,114.00
DEI Earnings Per Adjusted Shares Outstanding		 -17.26 -14.83 -6.65 -3.95 -4.46 - 6.49 0.40 -0.61 -0.47 -0.51
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -52.05% 1,823.98% 2,131.40% 2,892.69% 1,779.79% 670.30% 258.77% -38.63% -91.41% -95.13% -99.47%
EBITDA Growth		 17.69% 23.75% 59.99% 76.17% 70.82% 79.88% 237.29% 120.42% 81.94% 78.26% -108.18%
EBIT Growth		 18.01% 20.68% 58.55% 74.47% 69.55% 79.50% 224.41% 117.65% 83.16% 78.75% -108.69%
NOPAT Growth		 17.74% 20.62% 58.35% 74.47% 68.75% 79.65% 277.40% 125.02% 83.57% 79.00% -106.08%
Net Income Growth		 17.00% 18.94% 57.53% 73.21% 68.61% 79.00% 219.71% 112.53% 80.36% 73.17% -110.91%
EPS Growth		 17.00% 18.94% 57.53% 81.67% 82.13% 88.09% 161.95% 106.13% 89.08% 84.12% -108.29%
Operating Cash Flow Growth		 21.08% 11.38% 22.94% 79.84% 92.23% 51.45% 4.98% 31.25% -145.35% 76.72% 89.08%
Free Cash Flow Firm Growth		 193.05% 74.48% -8.76% -160.43% -142.95% -174.01% -107.24% -570.45% -923.73% -380.42% 30.10%
Invested Capital Growth		 -92.61% -29.90% -2.92% 0.02% -2.92% 7.40% 52.27% 60.79% 68.11% 66.42% 33.87%
Revenue Q/Q Growth		 123.41% 98.88% 543.39% 4.69% 40.33% -18.50% 199.66% -82.09% -80.35% -53.81% -67.65%
EBITDA Q/Q Growth		 3.29% 17.46% 47.49% 43.14% -18.40% 43.07% 458.23% -91.54% -204.72% 31.46% -34.73%
EBIT Q/Q Growth		 2.50% 13.88% 48.01% 41.51% -16.26% 42.02% 415.58% -91.70% -210.90% 26.83% -28.98%
NOPAT Q/Q Growth		 2.52% 13.86% 47.89% 41.66% -19.34% 43.91% 554.24% -91.77% -178.35% 28.29% -31.45%
Net Income Q/Q Growth		 1.84% 13.39% 47.47% 40.01% -15.01% 42.06% 399.46% -93.72% -280.27% 20.85% -21.70%
EPS Q/Q Growth		 1.84% 13.39% 47.47% 45.13% 5.48% 41.98% 305.88% -94.57% -268.42% 15.63% -7.41%
Operating Cash Flow Q/Q Growth		 2.75% 1.83% 41.25% 64.05% 62.53% -513.46% -14.99% 73.99% -33.74% 41.79% 46.06%
Free Cash Flow Firm Q/Q Growth		 18.24% -128.76% -146.97% 28.04% 15.96% -83.47% -86.78% -132.81% -28.32% 13.90% 72.82%
Invested Capital Q/Q Growth		 -4.82% 1.49% 4.24% -1.11% -7.91% 11.37% 50.65% 16.93% 12.23% 6.68% 2.79%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -3,210.66% -1,332.48% -108.75% -59.07% -49.84% -34.81% 41.62% 19.65% -104.75% -155.42% -647.29%
Operating Margin		 -3,255.94% -1,410.21% -114.22% -63.66% -54.14% -37.26% 39.53% 18.19% -103.50% -160.69% -652.91%
EBIT Margin		 -3,257.20% -1,410.49% -113.97% -63.68% -52.75% -37.53% 39.52% 18.32% -103.39% -163.76% -652.91%
Profit (Net Income) Margin		 -3,264.59% -1,421.68% -116.07% -66.51% -54.51% -38.75% 38.73% 13.58% -124.62% -213.54% -803.29%
Tax Burden Percent		 99.97% 100.02% 100.08% 100.00% 99.92% 99.85% 100.00% 99.87% 100.66% 100.00% 100.00%
Interest Burden Percent		 100.25% 100.78% 101.76% 104.45% 103.41% 103.42% 97.99% 74.25% 119.75% 130.40% 123.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.13% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -425.97% -2,014.86% 1,398.03% 350.14% 188.38% 86.92% 20.40% -7.94% -36.80% -48.15% 20.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -53.11% -44.63% -16.93% -21.84% -31.97% -35.24% 69.46% 44.82% -181.73% -305.84% -368.32%
Return on Assets (ROA)		 -53.23% -44.98% -17.24% -22.82% -33.03% -36.39% 68.06% 33.24% -219.04% -398.81% -453.16%
Return on Common Equity (ROCE)		 -425.97% -2,014.86% 1,398.03% 350.14% 188.38% 86.92% 20.40% -7.94% -36.80% -48.15% 20.49%
Return on Equity Simple (ROE_SIMPLE)		 570.93% 0.00% 237.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -49 -42 -22 -13 -15 -8.54 39 3.19 -2.50 -1.79 -2.36
NOPAT Margin		 -2,279.16% -987.14% -79.95% -44.56% -37.89% -26.08% 39.53% 18.17% -72.45% -112.48% -457.03%
Net Nonoperating Expense Percent (NNEP)		 -11.41% -12.53% -7.84% -6.65% -7.86% -8.78% -2.62% -2.79% -4.44% -6.31% -15.99%
Return On Investment Capital (ROIC_SIMPLE)		 - 42.30% 22.25% 11.51% 16.82% 8.78% -70.46% -9.11% 6.83% 4.66% 6.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 572.83% 269.38% 40.62% 31.12% 25.93% 28.82% 11.69% 37.06% 115.46% 268.15% 697.09%
R&D to Revenue		 2,660.80% 1,166.51% 166.34% 116.38% 109.29% 87.69% 27.95% 41.59% 84.71% -13.98% 31.78%
Operating Expenses to Revenue		 3,355.94% 1,515.29% 214.22% 163.66% 154.14% 137.26% 60.47% 81.81% 203.50% 260.69% 752.91%
Earnings before Interest and Taxes (EBIT)		 -70 -60 -31 -18 -21 -12 39 3.22 -3.57 -2.61 -3.37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -69 -57 -30 -17 -20 -11 41 3.45 -3.62 -2.48 -3.34
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 32.94 6.10 2.39 0.66 0.40 0.59 0.17 0.24 0.66 1.08 1.67
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.94 4.30 3.99 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.59% 23.25% 25.06% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 10.36 0.05 1.05 0.09 0.00 0.26 0.10 0.13 0.57 1.01 1.31
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.84 2.97 3.19 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.78 3.32 3.40 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.93 3.32 3.40 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -2.71 -10.76 7.55 1.83 1.20 0.48 0.39 0.40 0.64 0.38 0.24
Leverage Ratio		 4.09 19.77 -14.01 -3.52 -2.34 -1.40 -1.48 -1.06 -1.36 -0.95 -0.89
Compound Leverage Factor		 4.10 19.93 -14.26 -3.67 -2.42 -1.45 -1.45 -0.78 -1.63 -1.24 -1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -14.72 -17.98 -17.71 -24.86 -20.25 -26.10 -40.45 -70.30 -88.11 -133.17 -140.44
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.50 0.72 0.59 0.42 0.59 0.48 0.57 1.70 1.02 0.82 2.16
Quick Ratio		 1.30 0.60 0.45 0.25 0.44 0.33 0.47 1.53 0.87 0.65 1.48
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 25 -7.20 -18 -13 -11 -20 -37 -86 -110 -95 -26
Operating Cash Flow to CapEx		 -18,272.60% -114,559.09% -23,316.54% -36,706.90% 0.00% -27,190.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 17.94 -6.12 -15.41 -10.13 -9.09 -19.39 -36.22 -88.22 -121.04 -105.97 -31.02
Operating Cash Flow to Interest Expense		 -36.81 -42.86 -25.68 -8.44 -3.37 -24.06 -27.67 -7.53 -10.77 -6.37 -3.70
Operating Cash Flow Less CapEx to Interest Expense		 -37.01 -42.90 -25.79 -8.46 -3.37 -24.15 -27.67 -7.53 -10.72 -5.75 -3.70
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.03 0.15 0.34 0.61 0.94 1.76 2.45 1.76 1.87 0.56
Accounts Receivable Turnover		 22.05 0.23 1.92 42.60 134.10 7.25 8.93 0.00 93.55 88.32 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.76 1.69 7.85 16.28 31.94 50.07 122.01 151.36 168.06 176.70 136.11
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 16.55 1,582.30 190.53 8.57 2.72 50.37 40.85 0.00 3.90 4.13 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 16.55 1,582.30 190.53 8.57 2.72 50.37 40.85 0.00 3.90 4.13 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -153 -151 -145 -146 -158 -140 -69 -57 -50 -47 -46
Invested Capital Turnover		 -0.04 -0.06 -0.24 -0.43 -0.65 -0.89 -1.87 -1.85 -1.46 -1.29 -0.40
Increase / (Decrease) in Invested Capital		 -74 -35 -4.10 0.03 -4.48 11 76 89 108 93 23
Enterprise Value (EV)		 47 0.39 36 5.50 -27 34 21 24 87 122 30
Market Capitalization		 150 52 83 41 40 77 35 46 101 130 39
Book Value per Share		 ($0.50) ($0.97) ($0.82) ($0.92) ($18.42) ($16.89) ($9.40) ($5.88) ($5.22) ($5.34) ($4.56)
Tangible Book Value per Share		 ($0.50) ($0.97) ($0.82) ($0.92) ($18.42) ($16.89) ($9.40) ($5.88) ($5.22) ($5.34) ($4.56)
Total Capital		 -51 -99 -98 -111 -91 -97 -55 -35 -37 -39 -37
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -103 -52 -46 -35 -67 -43 -14 -22 -14 -8.48 -8.36
Capital Expenditures (CapEx)		 0.28 0.04 0.13 0.03 0.00 0.09 0.00 0.00 -0.04 -0.56 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -63 -92 -121 -121 -131 -112 -35 -12 -13 -11 -1.83
Debt-free Net Working Capital (DFNWC)		 40 -40 -74 -86 -64 -70 -21 10 0.38 -2.71 6.53
Net Working Capital (NWC)		 40 -40 -74 -86 -64 -70 -21 10 0.38 -2.71 6.53
Net Nonoperating Expense (NNE)		 21 18 9.88 6.29 6.68 4.15 0.79 0.81 1.80 1.61 1.79
Net Nonoperating Obligations (NNO)		 -103 -52 -46 -35 -67 -43 -14 -22 -14 -8.48 -8.36
Total Depreciation and Amortization (D&A)		 1.00 3.32 1.43 1.32 1.17 0.89 2.05 0.24 -0.05 0.13 0.03
Debt-free, Cash-free Net Working Capital to Revenue		 -1,385.89% -1,075.80% -347.63% -194.42% -130.88% -87.11% -17.37% -6.42% -8.78% -9.27% -7.92%
Debt-free Net Working Capital to Revenue		 872.02% -470.75% -213.97% -137.62% -63.84% -54.04% -10.37% 5.41% 0.25% -2.24% 28.21%
Net Working Capital to Revenue		 872.02% -470.75% -213.97% -137.62% -63.84% -54.04% -10.37% 5.41% 0.25% -2.24% 28.21%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($16.50) ($356.75) ($5.75) ($3.10) ($2.93) ($1.70) $3.53 $0.20 ($0.32) ($0.27) ($0.29)
Adjusted Weighted Average Basic Shares Outstanding		 4.26M 169.44K 5.62M 6.14M 7.47M 7.49M 10.76M 12.20M 13.56M 12.54M 14.08M
Adjusted Diluted Earnings per Share		 ($16.50) ($356.75) ($5.75) ($3.10) ($2.93) ($1.70) $3.50 $0.19 ($0.32) ($0.27) ($0.29)
Adjusted Weighted Average Diluted Shares Outstanding		 4.26M 169.44K 5.62M 6.14M 7.47M 7.49M 10.85M 12.31M 13.56M 12.72M 14.08M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($356.75) $0.00 $0.00 $0.00 ($1.70) $0.00 $0.00 $0.00 ($0.27) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.08M 4.77M 4.82M 4.92M 5.76M 5.86M 5.96M 7.02M 7.21M 8.18M 9.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -49 -42 -22 -13 -15 -8.54 27 3.19 -2.50 -1.79 -2.36
Normalized NOPAT Margin		 -2,279.16% -987.14% -79.95% -44.56% -37.89% -26.08% 27.67% 18.17% -72.45% -112.48% -457.03%
Pre Tax Income Margin		 -3,265.48% -1,421.43% -115.98% -66.51% -54.56% -38.81% 38.73% 13.60% -123.81% -213.54% -803.29%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -49.92 -51.00 -27.04 -14.45 -17.92 -12.09 38.14 3.31 -3.93 -2.92 -4.06
NOPAT to Interest Expense		 -34.93 -35.69 -18.97 -10.11 -12.87 -8.40 38.15 3.29 -2.75 -2.01 -2.84
EBIT Less CapEx to Interest Expense		 -50.12 -51.04 -27.15 -14.47 -17.92 -12.18 38.14 3.31 -3.88 -2.30 -4.06
NOPAT Less CapEx to Interest Expense		 -35.13 -35.73 -19.08 -10.14 -12.87 -8.49 38.15 3.29 -2.70 -1.39 -2.84
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Atara Biotherapeutics’ latest quarter shows a company still under heavy financial strain, but with a slightly improved liquidity position versus the prior quarter. Revenue in Q1 2026 was only $516,000, while the company posted a net loss of $4.15 million and negative operating cash flow of $3.07 million. That said, Atara ended the quarter with $8.36 million in cash and equivalents, up from $5.74 million at the end of Q3 2025, helped by common equity issuance.

What stands out most is the balance sheet structure: Atara remains deeply leveraged with $57.31 million in total liabilities and negative shareholders’ equity of $37.31 million. This means the company is still reliant on external financing and/or asset sales to fund operations, which is a major risk for retail investors.

Quarter-over-quarter trends were mixed. Revenue fell sharply from $1.6 million in Q4 2025 to $516,000 in Q1 2026, and the net loss widened slightly from $3.41 million to $4.15 million. Operating expenses also remained several times larger than revenue, showing that the business has not yet reached sustainable operating leverage.

Looking back over the past year, the bigger story is volatility. Atara posted a brief profitable stretch in Q2 2025, when revenue jumped to $17.6 million and the company earned $2.39 million in net income. But that improvement did not last, and results deteriorated again in subsequent quarters as revenue dropped and losses returned.

Cash flow has also been inconsistent. The company generated positive operating cash flow in some prior periods only because of large working-capital swings and financing actions, while more recent quarters have shown recurring operating cash burn. In Q1 2026, financing inflows of $2.95 million offset operating cash use, but that is not a long-term solution.

  • Cash and equivalents increased sequentially to $8.36 million from $5.74 million in Q3 2025, giving the company a bit more near-term flexibility.
  • Atara raised $2.95 million through common equity issuance in Q1 2026, which helped offset operating losses.
  • Revenue was higher than the year-ago Q1 2024 level of $27.36 million? No, this latest quarter was much smaller, but the company has shown it can produce meaningful revenue in certain periods, such as Q2 2025 and Q4 2024.
  • Research and development spending was modest in Q1 2026 at $164,000, suggesting a tighter cost structure, though it may also reflect limited development activity.
  • Deferred revenue and other liabilities remain material, which can provide some near-term operating support but also signals ongoing obligations.
  • The company’s results remain highly volatile quarter to quarter, making trend analysis difficult and increasing investment uncertainty.
  • Q1 2026 revenue was only $516,000, down sharply from $1.6 million in Q4 2025 and far below prior periods like Q2 2025.
  • Net loss widened to $4.15 million in Q1 2026, and the company has not established durable profitability.
  • Operating cash flow was negative $3.07 million in Q1 2026, continuing a pattern of cash burn.
  • Shareholders’ equity remains negative at $37.31 million, reflecting accumulated losses and a stressed capital structure.
  • Total liabilities of $57.31 million exceed total assets of $19.997 million, underscoring balance sheet risk.
  • Revenue and earnings swung sharply in prior quarters, including a large loss in Q4 2024 and a brief profit in Q2 2025, showing the business is not stable yet.

Bottom line: Atara Biotherapeutics remains a high-risk turnaround story. The company has enough liquidity for the near term, but its weak revenue base, recurring losses, negative equity, and dependence on financing make the stock speculative and highly sensitive to any operational or capital-raising developments.

07/26/26 02:59 PM ETAI Generated. May Contain Errors.

Atara Biotherapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Atara Biotherapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Over the last 10 years, Atara Biotherapeutics' net income changed from -$57.22 million in 2015 to $32.69 million in 2025, a change of -157.1%. See where experts think Atara Biotherapeutics is headed by visiting Atara Biotherapeutics' forecast page.

Atara Biotherapeutics' total operating income in 2025 was $35.86 million, based on the following breakdown:
  • Total Gross Profit: $120.77 million
  • Total Operating Expenses: $84.91 million

Over the last 10 years, Atara Biotherapeutics' total revenue changed from $0.00 in 2015 to $120.77 million in 2025, a change of 12,077,200,000.0%.

Atara Biotherapeutics' total liabilities were at $58.74 million at the end of 2025, a 71.5% decrease from 2024, and a 494.8% increase since 2015.

In the past 10 years, Atara Biotherapeutics' cash and equivalents has ranged from $8.48 million in 2025 to $200.40 million in 2020, and is currently $8.48 million as of their latest financial filing in 2025.

Over the last 10 years, Atara Biotherapeutics' book value per share changed from 11.01 in 2015 to -5.34 in 2025, a change of -148.5%.


Related Companies

Financial statements for NASDAQ:ATRA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
BlackRock's $2.8B Clue (most investors missed)
BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...
Awesomely | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
The invention Elon called the greatest in history
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel